Shares of Coherus (NASDAQ: CHRS) rallied as much as 21.7% early Monday, then gave up its gains to trade up around 2.4% as of 2:40 p.m. ET. This occurred after the company announced an agreement to ...

UDENYCA net product sales were $50.9 million in Q2 2024, an increase of 19% compared to $42.7 million in Q1 2024 and a 60% increase compared to $31.7 million in Q2 2023. Total unit demand increased 25 ...

A disappointing quarter combined with a set of analyst price target cuts -- and even a recommendation downgrade -- made Coherus BioSciences (NASDAQ: CHRS) a stock to avoid this week. As of ...

REDWOOD CITY, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS), today announced that effective December 20, 2023, the compensation committee of the Company’s board of ...

(Reuters) -Coherus BioSciences Inc said on Thursday it plans to launch a biosimilar of AbbVie Inc's Humira in July at a list price of $995 per carton, representing a discount of about 85% from the ...

Analysts have provided the following ratings for Coherus BioSciences (NASDAQ:CHRS) within the last quarter: These 4 analysts have an average price target of $18.0 versus the current price of Coherus ...

Coherus BioSciences (NASDAQ:CHRS) is gearing up to announce its quarterly earnings on Thursday, 2025-11-06. Here's a quick overview of what investors should know before the release. Analysts are ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Illustration photo shows various medicine pills in their original packaging (Reuters) -Coherus BioSciences said on ...

Coherus BioSciences stock initially jumped after the announcement of a deal to sell Cimerli to Sandoz. However, shares are now sinking with investors reminded of the financial challenges that Coherus ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) shares are trading higher Monday after the company announced the FDA-approval of Loqtorzi in all lines of treatment for recurrent or metastatic nasopharyngeal ...

In a press release late yesterday, Coherus announced it has entered into an agreement with Pharmakon Advisors to revise the terms of its loan agreement entered in January 2022. After Coherus closes ...